A pivotal study of 4SC-202 in combination with a checkpoint inhibitor in PD-(L)1 refractory patients with advanced Merkel cell carcinoma (MCC).
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Domatinostat (Primary)
- Indications Merkel cell carcinoma
- Focus Registrational; Therapeutic Use
- 27 Dec 2018 According to a 4SC media release, this trial is expected to be initiated in 2H 2019.
- 03 Jul 2018 According to the 4SC media release, this trial is expected to initiate in 2019.
- 21 Mar 2018 According to a 4SC media release, taking data from SENSITIZE and EMERGE study, this study will be initiated.